Key result
Clinically significant drug-drug interactions are linked to ~28% higher CV death in older AF patients.
Why the study?
Does the presence of potentially clinically significant drug-drug interactions increase the risk of adverse clinical outcomes in older adults with atrial fibrillation and multimorbidity?
Cohort (n=192,716)
Does the presence of potentially clinically significant drug-drug interactions increase the risk of adverse clinical outcomes in older adults with atrial fibrillation and multimorbidity?
Hazard Ratio: 1.28 (95% CI 1.24–1.32)
Absolute Event Rate: 7.3% vs 4.19%
Potentially clinically significant drug-drug interactions are highly prevalent (37.5%) in older adults with atrial fibrillation and multimorbidity, and are associated with increased risks of cardiovascular death, hospitalization, and falls.
May warrant DDI vigilance in older AF; leaves open whether mitigation improves survival.
PURPOSE: Current research on potentially clinically significant drug-drug interactions (DDIs) in individuals with atrial fibrillation (AF) has predominantly focused on DDIs involving direct oral anticoagulants (DOACs), with limited evidence regarding other medications. Our study aimed to: (i) assess the overall prevalence of DDIs; (ii) investigate potential demographic correlates of DDIs; and (iii) examine the association of DDIs with adverse clinical outcomes in a nationwide cohort of older adults with AF and multimorbidity. METHODOLOGY: Data from the Swedish national registers were linked to establish a cohort with a 2-year follow-up of adults ≥ 65 years who, on 1 January 2017, had a diagnosis of AF, ≥ 1 comorbidity and were prescribed ≥ 2 medications (n = 192,716). This study describes the prevalence of 72 potentially clinically significant DDIs from an adapted explicit international consensus list and a review focused specifically on DDIs involving DOACs. Correlates of DDIs were assessed through logistic regressions. Cox regression analyses were conducted to examine the association between DDIs and adverse clinical outcomes: overall and cardiovascular (CV) mortality, overall and CV hospitalisation, stroke, bleeding, and falls. RESULTS: In the overall population, 37.5% presented with ≥ 1 potential DDI, with CV (33.8%) and central nervous system (CNS) drugs (12.4%) most frequently involved. Sex, age, and civil status were most consistently associated with DDIs. Individuals with ≥ 1 DDI had a higher hazard of CV death (hazard ratio 1.28 95% confidence interval (CI) [1.24-1.32]), CV hospitalisation (1.12 [1.10-1.15]) and falls (1.06 [1.02-1.09]). DDIs with DOACs were associated with gastrointestinal bleeding (2.80 [1.35-5.81]). DDIs with CNS drugs were associated with stroke (1.19 [1.09-1.29]) and falls (1.32 [1.27-1.39]). CONCLUSION: Potentially clinically significant DDIs were prevalent in older adults with AF and multimorbidity, with adverse clinical implications. Identifying these high-risk groups is essential for preventive strategies and effective clinical management.
No takes yet. Share an insight, caveat, or question.
Amrouch et al. (2026) conducted a cohort in Atrial fibrillation and multimorbidity (n=192,716). Potentially clinically significant drug-drug interactions (DDIs) vs. No potentially clinically significant DDIs was evaluated on Cardiovascular death (HR 1.28, 95% CI 1.24-1.32). Exposure to at least one potentially clinically significant drug-drug interaction was associated with a higher hazard of cardiovascular death (HR 1.28) in older adults with atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: